Levothyroxine Sodium Injection, Solution
FDA Label NDC 24201-002

35 label sections · Submitted to the FDA by Hikma Pharmaceuticals Usa Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Hikma Pharmaceuticals Usa Inc. for the product Levothyroxine Sodium (NDC 24201-002). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: not for treatment of obesity or for weight loss, 1 indications and usage, 2.1 dosage, 2.2 dosing in the elderly and in patients with cardiovascular disease, 2.3 administration instructions, 3 dosage forms and strengths, 4 contraindications, 5.1 risk of cardiac complications in elderly and in patients with cardiovascular disease, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.